Symbiotec Pharmalab
Price band ₹938–988 · Issue ₹1757.00 Cr
Market attention score 36.6 (how ranked)
IPO alerts
Get notified for open, close, allotment. Delivered in-app, push, and email.
Automated WhatsApp broadcasts aren't available yet — use this to ping yourself or a group.
Capital required
Approximate retail outlay for Symbiotec Pharmalab at the issue price band (lot × lots).
Est. capital
₹14,070 – ₹14,820
Lot size 15 · up to ₹988/share
Prefer smaller tickets before listing? Explore unlisted & pre-IPO shares.
Opens
24 Aug 2026
Closes
27 Aug 2026
Allotment
28 Aug 2026
Listing
1 Sept 2026
Lot size
15
GMP
+22.27%
At a glance
IPO Open Mon, Aug 24, 2026 IPO Close Thu, Aug 27, 2026 Price Band ₹938 to ₹988 Market Cap * ₹6,244.43 Cr * on Upper Price IPO Details IPO Date 24 to 27 Aug, 2026 Listing Date Tue, Sep 1, 2026 T Face Value ₹ 2 per share Price Band ₹938 to ₹988 Lot Size 15 Shares Sale Type Fresh capital cum OFS Issue Type Bookbuilding IPO Listing At BSE, NSE Employee Discount ₹ 90.00 Total Issue Size 1,77,86,442 shares (agg. up to ₹ 1,757 Cr) Fresh Issue 15,21,261 shares (agg. up to ₹ 150 Cr) Offer for Sale 1,62,65,181 shares of ₹ 2 (agg. up to ₹ 1,607 Cr) Share Holding Pre Issue 6,16,81,496 shares Share Holding Post Issue 6,32,02,757 shares IPO Timetable (Tentative) IPO Open Mon, Aug 24, 2026 IPO Close Thu, Aug 27, 2026 Allotment Fri, Aug 28, 2026 Refund Mon, Aug 31, 2026 Credit of Shares Mon, Aug 31, 2026 Listing Tue, Sep 1, 2026 IPOs Timetable Issue Reservation Investor Category Shares QIB Not more than 50% of the Net Offer Retail Not less than 35.00% of the Net Offer NII Not less than 15% of the Net Offer IPO Lot Size Investors can bid for a minimum of 15 shares and in multiples thereof. Application Lots Shares Amount Retail (Min) 1 15 ₹14,820 Retail (Max) 13 195 ₹1,92,660 S-HNI (Min) 14 210 ₹2,07,480 S-HNI (Max) 67 1,005 ₹9,92,940 B-HNI (Min) 68 1,020 ₹10,07,760 IPO Subscription Details Investor Category Reservations Category Limit Cut-off RII Up to ₹2 Lakhs Yes sNII ₹2 Lakhs – ₹10 Lakhs No bNII Above ₹10 Lakhs No Employee (EMP) Up to ₹5 Lakhs Yes Employee + RII/NII Up to ₹5Lakhs (EMP) + RII/NII limits Yes (EMP/RII) About Symbiotec Pharmalab Ltd. Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions.
With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations.
Overview
Symbiotec Pharmalab IPO is a book build issue of ₹1,757.00 crores. The issue is a combination of fresh issue of 0.15 crore shares aggregating to ₹150.00 crores and offer for sale of 1.63 crore shares aggregating to ₹1,607.00 crores.
Symbiotec Pharmalab IPO opens for subscription on Aug 24, 2026 and closes on Aug 27, 2026. The allotment for the Symbiotec Pharmalab IPO is expected to be finalized on Aug 28, 2026. Symbiotec Pharmalab IPO will list on NSE and BSE with a tentative listing date fixed as Sep 1, 2026.
Symbiotec Pharmalab IPO is set issue price band at ₹938 to ₹988 per share. The lot size for an application is 15 shares. The minimum amount of investment required by an individual investor (retail) is ₹14,820 (15 shares) (based on upper price).
JM Financial Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Symbiotec Pharmalab IPO RHP for detailed Information.
Issue details
IPO Date
24 to 27 Aug, 2026
Listing Date
Tue, Sep 1, 2026T
Face Value
₹2 per share
Price Band
₹938 to ₹988
Lot Size
15 Shares
Sale Type
Fresh capital cum OFS
Issue Type
Bookbuilding IPO
Listing At
BSE, NSE
Employee Discount
₹90.00
Lot size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,820 |
| Retail (Max) | 13 | 195 | ₹1,92,660 |
| S-HNI (Min) | 14 | 210 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1,005 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1,020 | ₹10,07,760 |
Issue reservation
| Investor Category | Shares |
|---|---|
| QIB | Not more than 50% of the Net Offer |
| Retail | Not less than 35.00% of the Net Offer |
| NII | Not less than 15% of the Net Offer |
About the company
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions.
With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations.
As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres.
Symbiotec Pharmalab focuses on research-driven manufacturing, quality compliance, and sustainable production processes. It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards.
- Global leadership in corticosteroid and steroidal hormone APIs.
- Long-standing relationships with domestic and international customers.
- Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record.
- Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers.
- Ability to leverage its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings.
Financials
| Metric | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Total Income | 872.26 | 755.98 | 723.33 |
| Profit After Tax | 109.90 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| NET Worth | 1,158.64 | 821.15 | 720.68 |
| Reserves and Surplus | 1,145.95 | 810.03 | 709.54 |
| Total Borrowing | 387.91 | 540.92 | 247.21 |
Amounts in ₹ Crore (restated)
Key performance indicators
| KPI | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| ROE | 11.19% | 12.66% |
| ROCE | 11.56% | 11.80% |
| RoNW | 9.48% | 11.79% |
| PAT Margin | 12.60% | 12.80% |
| EBITDA Margin | 26.59% | 27.26% |
| NAV | 184.69 | 150.17 |
| Price to Book Value | 5.35 | 6.58 |
Valuation
Valuation Metric
Pre IPO
EPS (₹)
17.82
P/E (x)
55.44
Market Cap at Offer Price
₹6,094Cr.
Shareholding
| Category | Pre IPO | Post IPO |
|---|---|---|
| Promoter and Promoter Group | 34.47% | |
| Public | 65.53% | |
| Total | 100% |
Objects of the issue
- — Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company
- — General corporate purposes
Intermediaries
Registrar
MUFG Intime India Pvt.Ltd.
Lead manager(s)
JM Financial Ltd., Avendus Capital Pvt.Ltd., Motilal Oswal Investment Advisors Ltd., Nomura Financial Advisory & Securities (India) Pvt.Ltd.
FAQs
How to apply in Symbiotec Pharmalab IPO through Zerodha?+
Zerodha customers can apply online in Symbiotec Pharmalab IPO using UPI as a payment gateway. Zerodha customers can apply in Symbiotec Pharmalab IPO by login into Zerodha Console (back office) and submitting an IPO application form. Steps to apply in Symbiotec Pharmalab IPO through Zerodha Visit the Zerodha website and login to Console. Go to Portfolio and click the IPOs link. Go to the ' Symbiotec Pharmalab IPO ' row and click the 'Bid' button. Enter your UPI ID, Quantity, and Price. Submit IPO application form. Visit the UPI App (net banking or BHIM ) to approve the mandate. Visit Zerodha IPO Application Process Review for more detail.
When Symbiotec Pharmalab IPO will open?+
The Symbiotec Pharmalab IPO opens on Mon, Aug 24, 2026 and closes on Thu, Aug 27, 2026.
What is the lot size of Symbiotec Pharmalab IPO?+
Symbiotec Pharmalab IPO lot size is 15 , and the minimum amount required for application is ₹14,820 .
How to apply for Symbiotec Pharmalab IPO?+
You can apply in Symbiotec Pharmalab IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha , Upstox , 5Paisa , Nuvama , HDFC Bank , and SBI Bank .
When is Symbiotec Pharmalab IPO allotment?+
The finalization of Basis of Allotment for Symbiotec Pharmalab IPO will be done on Friday, August 28, 2026 , and the allotted shares will be credited to your demat account by Mon, Aug 31, 2026 . Check the Symbiotec Pharmalab IPO allotment status .
When is Symbiotec Pharmalab IPO listing date ?+
The Symbiotec Pharmalab IPO listing date is not yet announced. The tentative date of listing is Tue, Sep 1, 2026 .
Aggregated from public IPO filings. GMP is unofficial grey-market chatter, not advice.